Symbol | Exchange | Currency |
|---|
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosed No limiting toxicities have been encountered during the trial to date. Patients are now being...
SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )) today announced publication of peer-reviewed data detailing the...
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC...
PALO ALTO, Calif. and SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), an innovative revenue-generating company focused on acquiring, developing and...
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D., Chairman, President and Chief Executive...
209) and median overall survival (OS) of 28.2 months.
Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The Company is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.
| Average | 21.000 (+1229.11% Upside) |
| High | 26 |
| Low | 16 |
| Price | 1.58 |
| No. of Analysts | 2 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Sell | Sell | Strong Sell |
| Technical Indicators | Neutral | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
| Summary | Neutral | Strong Buy | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 194.40 | 205.10 | 191.55 | -12.70 | -6.13% | 3.30M | London | |||
| 14.48 | 15.50 | 14.50 | -1.34 | -8.46% | 540.16K | London | |||
| 4.40 | 4.55 | 4.40 | +0.05 | +1.14% | 7.29M | London | |||
| 85.08 | 89.56 | 83.18 | -5.88 | -6.46% | 19.65M | London | |||
| 172.30 | 181.35 | 172.30 | -10.05 | -5.51% | 8.14M | London | |||
| 2,338.00 | 2,382.00 | 2,308.00 | -56.0 | -2.34% | 1.02M | London | |||
| 115.10 | 121.00 | 114.60 | -7.00 | -5.73% | 523.20K | London | |||
| 156.25 | 158.00 | 152.50 | 0.00 | 0.00% | 0.00 | London | |||
| 125.45 | 142.20 | 124.95 | -16.80 | -11.81% | 4.52M | London | |||
| 221.10 | 225.80 | 216.30 | -5.50 | -2.43% | 21.84M | London | |||
| 0.70 | 0.70 | 0.70 | +0.175 | +33.33% | 60.61M | London | |||
| 622.00 | 664.00 | 622.00 | -10.00 | -1.58% | 510.76K | London | |||
| 323.40 | 341.80 | 317.80 | -47.30 | -12.76% | 7.40M | London | |||
| 1,992.00 | 2,065.00 | 1,950.00 | -68.0 | -3.30% | 429.73K | London | |||
| 3,269.50 | 3,331.00 | 3,241.50 | -122.5 | -3.61% | 2.81M | London |